I-BET151 (GSK1210151A)

For research use only. Not for use in humans.

目录号:S2780

I-BET151 (GSK1210151A) Chemical Structure

CAS No. 1300031-49-5

I-BET151 (GSK1210151A)是一种新型,选择性的BET抑制剂,作用于BRD2,无细胞试验中BRD3BRD4IC50分别为0.5 μM, 0.25 μM和0.79 μM。

规格 价格 库存 购买数量  
RMB 1382.25 现货
RMB 2231.18 现货
RMB 7130.63 现货
RMB 10401.3 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的I-BET151 (GSK1210151A)发表文献27篇:

产品安全说明书

Epigenetic Reader Domain抑制剂选择性比较

生物活性

产品描述 I-BET151 (GSK1210151A)是一种新型,选择性的BET抑制剂,作用于BRD2,无细胞试验中BRD3BRD4IC50分别为0.5 μM, 0.25 μM和0.79 μM。
特性 优化I-BET151,使其有效及选择性靶向作用于BET,同时增强体内药代动力学和终末半衰期,以使延长体内研究。
靶点
BRD3 [1]
(Cell-free assay)
BRD2 [1]
(Cell-free assay)
BRD4 [1]
(Cell-free assay)
0.25 μM 0.5 μM 0.79 μM
体外研究

I-BET151有效,选择性作用于多种不同蛋白类型,如COX-2, P450, Aurora B, GSK3β, PI3K-γ, GPCR, 离子通道,转运体。与I-BET762 (GSK525762A)类似, I-BET151 对BRD2, BRD3 和BRD4具有高的结合亲和力,Kd为0.02-0.1 μM,作用于人类外周血单核细胞(PBMC)和全血(WB)以及大鼠WB,显著抑制脂多糖刺激的IL-6细胞因子产生,IC50分别为0.16 μM, 1.26 μM, 和 1.26 μM。I-BET151(0.5 or 5 μM)作用于HL60核提取物,抑制BETs(BRD2, BRD3, BRD4, 和 BRD9)而非23种其他溴区蛋白结合到乙酰化的组蛋白肽。I-BET151有效作用于含不同 MLL融合的细胞系,如MV4;11, RS4;11, MOLM13, 和NOMO1 细胞, IC50为15-192 nM。一致的是,I-BET151完全消除MLL融合驱动的白血病(MOLM13)而非酪氨酸激酶激活(K562)驱动的白血病的菌落形成潜力。I-BET151也有效作用于液体培养和转化MLL-ENL或MLL-AF9的原代小鼠祖细胞的克隆形成实验。I-BET151作用于由不同的MLL融合(分别含MLL-AF9和MLL-AF4的MOLM13和MV4;11)而非K562细胞驱动的MLL融合细胞系,显著诱导细胞凋亡和G0/G1期停滞,可能是由于通过抑制BRD3/4,PAFc和SEC组分招募到转录起始位点(TSS),而抑制BCL-2,C-MYC和CDK6的转录。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV4;11 NYLKemV4[3m2b4TvfIlkcXS7IHHzd4F6 M3P0Tp4yODBizszN NHfXZ29FVVOR M{\RRWlEPTB;Mk[gcm0> M3O4U|IyQTZ2M{Sw
RS4;11 NV3o[ZZC[3m2b4TvfIlkcXS7IHHzd4F6 Mon4glExOCEQvF2= NYDre2VzTE2VTx?= NUnEbXo5UUN3ME2xPVIhdk1? MlTuNlE6PjR|NEC=
MOLM13 NYXYN3N5[3m2b4TvfIlkcXS7IHHzd4F6 MlPSglExOCEQvF2= NELPO2hFVVOR M4XXW2lEPTB;MUKwJI5O MUiyNVk3PDN2MB?=
NOMO1 Mn\uZ5l1d3SxeHnjbZR6KGG|c3H5 M{\scJ4yODBizszN NIS5TpRFVVOR NULNR5AxUUN3ME2xOUBvVQ>? M1naVFIyQTZ2M{Sw
HEL M3HqR4N6fG:2b4jpZ4l1gSCjc4PhfS=> MknrglExOCEQvF2= MVnEUXNQ NF\ZSmlKSzVyPUGg{txO NV3mSWt4OjF7NkSzOFA>
K562 NUHjWIFj[3m2b4TvfIlkcXS7IHHzd4F6 MX;+NVAxKM7:TR?= M1PRUWROW09? MYfJR|UxRjFyMDFOwG0> NFnnem4zOTl4NEO0NC=>
MEG01 MmTkZ5l1d3SxeHnjbZR6KGG|c3H5 MWr+NVAxKM7:TR?= MYLEUXNQ M1Xtb2lEPTB;MkWg{txO MYSyNVk3PDN2MB?=
HL60 MnL5Z5l1d3SxeHnjbZR6KGG|c3H5 Mnv3glExOCEQvF2= NXz2VIVbTE2VTx?= Mni4TWM2OD16OUCgcm0> NWL4ToU{OjF7NkSzOFA>
MV4;11 MYrBdI9xfG:|aYOgZZN{[Xl? NISxR5Z,OTByIN88US=> NEnReHVFVVOR Ml3xbY5lfWOnczDhdI9xfG:|aYO= NYXacnBVOjF7NkSzOFA>
MOLM13 NHi4SnVCeG:ydH;zbZMh[XO|YYm= NEHxXYJ,OTByIN88US=> MULEUXNQ MWTpcoR2[2W|IHHwc5B1d3Orcx?= MoDCNlE6PjR|NEC=
MV4;11 MmrHSpVv[3Srb36gZZN{[Xl? M1uxeGROW09? MUHk[YNz\WG|ZYOgeIhmKHKnY4L1bZRu\W62IH;mJGJTTDNxNDDhcoQhcW2yYXny[YQhemWlcoXpeI1mdnRib3[gR2RMQSCjbnSgVGFHOSC2bzD0bIUhfHKjboPjdolxfGmxbnHsJJN1[XK2IIPpeIU> MlzmNlE6PjR|NEC=
PBMC NInieFlHfW6ldHnvckBie3OjeR?= MnXvSG1UVw>? MV3pcohq[mm2czDJUE03KHerdHigdGlEPTBib3[gOk44 Mmr0NlI1OzdzMUW=
A2 NYKwOVNZTnWwY4Tpc44h[XO|YYm= MkDhglExKM7:TR?= MlHTSG1UVw>? Mn7hdoVi[3SrdnH0[ZMhdGG2ZX70JGhKXi1z NIL6XWUzOzJ3NUKxPC=>
A72 Ml\NSpVv[3Srb36gZZN{[Xl? M4\nOJ4yOCEQvF2= NYrnVmFQTE2VTx?= MVvy[YFkfGm4YYTld{Bt[XSnboSgTGlXNTF? M4W0RlI{OjV3MkG4
BC1 Ml65S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M3W5VJ4yKM7:TR?= MlTwSG1UVw>? NW\tTnBrUUN3ME2yNlAhdk1? NIXJUYQzOzd7MkS0PC=>
BC3 NET4[HdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MoDxglEh|ryP MoP3SG1UVw>? MUnJR|UxRTR4MDDuUS=> NYr2XIJOOjN5OUK0OFg>
BCBL1 NVTYSIFKT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NYrI[HlFhjFizszN NIe1fpNFVVOR NXXDeFVYUUN3ME2zN|Ahdk1? NUfneFNQOjN5OUK0OFg>
BJAB M{\pSGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NVnLT3c3hjFizszN Ml;JSG1UVw>? NUfRWlVUUUN3ME25O|Ahdk1? MoTCNlM4QTJ2NEi=
Namalwa MYnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M33S[54yKM7:TR?= MVnEUXNQ NIPVOYZKSzVyPUm3NEBvVQ>? NUPBXnNbOjN5OUK0OFg>
Jurkat MmruS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MX7+NUDPxE1? NVvpOFRFTE2VTx?= NITFdZRKSzVyPUGyNlAhdk1? NWLnXFNqOjN5OUK0OFg>
MM1S Mmf0S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? Mk\CglEh|ryP NFvjO2ZFVVOR NUnjOWsxUUN3ME23OlAhdk1? NVy0R2s1OjN5OUK0OFg>
U266 M{jz[Wdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MXj+NUDPxE1? M4\mPWROW09? NVrWbVl6UUN3ME25OVAhdk1? NXLPeZJCOjN5OUK0OFg>
UM-PEL-1 NYrJOGN4T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NEfvR|F,OSEQvF2= MVvEUXNQ NXy4OJVFUUN3ME2yNVAhdk1? MV2yN|c6OjR2OB?=
UM-PEL-3 NX7Kb|FET3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NXrwWJV1hjFizszN MXfEUXNQ NYjUSFBxUUN3ME2xPFAhdk1? MXSyN|c6OjR2OB?=
BC1 NUT4bZZ[TnWwY4Tpc44h[XO|YYm= MoHsOVAxKG6P NWf5SZRyTE2VTx?= M1X3WYlv\HWlZYOgZ4VtdC2leXPs[UBienKnc4S= NGXWXWgzOzd7MkS0PC=>
BC3 MVHGeY5kfGmxbjDhd5NigQ>? NF7ROXU2ODBibl2= MmnxSG1UVw>? MkO0bY5lfWOnczDj[YxtNWO7Y3zlJIFzemW|dB?= MVyyN|c6OjR2OB?=
BC1 M3rXdmZ2dmO2aX;uJIF{e2G7 M{PjUlgxOCCwTR?= M4nXUGROW09? NV7sPGJZemWmdXPld{BkNU27YzDwdo91\WmwIHzleoVtew>? MmHkNlM4QTJ2NEi=
BC3 MYXGeY5kfGmxbjDhd5NigQ>? Mli1PFAxKG6P NXj0ZmFCTE2VTx?= MV;y[YR2[2W|IHOtUZlkKHC{b4TlbY4hdGW4ZXzz MljjNlM4QTJ2NEi=
H929 MnfLSpVv[3Srb36gZZN{[Xl? M4LWPZ4yKM7:TR?= M3zKfmROW09? Mk\PbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dB?= MnLONlQ{OzV2OUm=
KMS12PE MY\GeY5kfGmxbjDhd5NigQ>? M1TEXJ4yKM7:TR?= NGju[XBFVVOR NV34WmxkcW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeC=> MXyyOFM{PTR7OR?=
KMS12BM MY\GeY5kfGmxbjDhd5NigQ>? MXH+NUDPxE1? NXrHPWY3TE2VTx?= MmSybY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dB?= NFLDeWkzPDN|NUS5PS=>
KMS18 MXvGeY5kfGmxbjDhd5NigQ>? NIjIPGJ,OSEQvF2= NUnocHpTTE2VTx?= M{\vNIlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4S= MX:yOFM{PTR7OR?=
KMS11 MlfySpVv[3Srb36gZZN{[Xl? MknGglEh|ryP NYPU[WxOTE2VTx?= NXKxOHV5cW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeC=> NHTufpQzPDN|NUS5PS=>
RPMI8226 NY\JVZJJTnWwY4Tpc44h[XO|YYm= NH;4do1,OSEQvF2= MlzxSG1UVw>? NHrufllqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0 NYCzWoI4OjR|M{W0PVk>
H929 NFzVbo1CeG:ydH;zbZMh[XO|YYm= NVG1U5JuhjFizszN MXvEUXNQ NF3IcGZqdmS3Y3XzJINmdGxiYYDvdJRwe2m| M4rBOlI1OzN3NEm5
KMS12PE MmLrRZBweHSxc3nzJIF{e2G7 MoLiglEh|ryP NGP2SJdFVVOR NVOwN3d5cW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= M16ybVI1OzN3NEm5
KMS12BM Moi3RZBweHSxc3nzJIF{e2G7 NF60TGR,OSEQvF2= NXnuOZRxTE2VTx?= Mn31bY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MkC2NlQ{OzV2OUm=
KMS18 MXLBdI9xfG:|aYOgZZN{[Xl? MkjWglEh|ryP NVn4eIlHTE2VTx?= NFrXfIJqdmS3Y3XzJINmdGxiYYDvdJRwe2m| MnXVNlQ{OzV2OUm=
KMS11 MV\BdI9xfG:|aYOgZZN{[Xl? NVG4SndRhjFizszN NVm0NlBpTE2VTx?= NH3GZ2lqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NHf5VpczPDN|NUS5PS=>
RPMI8226 M4[4eGFxd3C2b4Ppd{Bie3OjeR?= MljCglEh|ryP Mkf2SG1UVw>? MX;pcoR2[2W|IHPlcIwh[XCxcITvd4l{ MVSyOFM{PTR7OR?=
U87MG Mne2SpVv[3Srb36gZZN{[Xl? M{\FVp4yOCEQvF2= MoTGSG1UVw>? NVv4d|hremWmdXPld{BWQDePRzDj[YxtfWyjcjDBWHAhf2m2aDDJR|UxKG:oIEGuNFUh|ryP MYWyOFQ6PjN6MR?=
A172 MYHGeY5kfGmxbjDhd5NigQ>? M2H1S54yOCEQvF2= MoDDSG1UVw>? NV21c|BKemWmdXPld{Bk\WyudXzhdkBCXFBid3n0bEBKSzVyIH;mJFEvOjhizszN NX7KSZh6OjR2OU[zPFE>
SW1783 MVLGeY5kfGmxbjDhd5NigQ>? Ml:1glExKM7:TR?= NXPLcnBDTE2VTx?= M{DSfJJm\HWlZYOgZ4VtdHWuYYKgRXRRKHerdHigTWM2OCCxZjCyMlY5KM7:TR?= NGrxN5UzPDR7NkO4NS=>
U87MG MlflSpVv[3Srb36gZZN{[Xl? M{LX[Z4yOCEQvF2= MmTiSG1UVw>? MXfpcoNz\WG|ZYOgdJJweG:{dHnvckBw\iClZXzsd{BqdiC2aHWgS|EwWyC2cnHud4l1cW:w NXzvdot7OjR2OU[zPFE>
RAW267.4 MVrGeY5kfGmxbjDhd5NigQ>? NW\vVIdHOSEQvF2= MlzXSG1UVw>? MmPKdoVlfWOnczDJUE03KHC{b3T1Z5Rqd25iaX7keYNm\CCkeTDMVHM> NH3SRWczPDh3OUCwPC=>
RAW267.4 MoXYSpVv[3Srb36gZZN{[Xl? M1T2clEh|ryP NVX4bIFHTE2VTx?= NW\qNpl5emWmdXPld{B1cGViYYPzc4Nq[XSrb36gZoV1f2WnbjDCVmQ1KGGwZDDhZ4V1gWyjdHXkJJA3PQ>? NW\TS4UyOjR6NUmwNFg>
Me007 MVXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NULyclU1hjFyMDFOwG0> NEHFVpRFVVOR MWrpcohq[mm2czD0bIUh\3Kxd4To MVWyOFkxPjF|Nx?=
SK-Mel-28 NEO5T2lIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NHXVVYZ,OTByIN88US=> M3\nO2ROW09? NWTEd4V5cW6qaXLpeJMhfGinIHfyc5d1cA>? NUHEOVlGOjR7ME[xN|c>
Mel-RMU NXvYOnFOT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MluxglExOCEQvF2= MmnoSG1UVw>? MkfBbY5pcWKrdIOgeIhmKGe{b4f0bC=> MmDVNlQ6ODZzM{e=
Mel-JD NFzWenZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= Mo\1glExOCEQvF2= NF\kR|BFVVOR NEfQS4lqdmirYnn0d{B1cGViZ4Lve5Rp NHLZbm8zPDlyNkGzOy=>
Mel-RM NFLrUWVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MoLmglExOCEQvF2= MUPEUXNQ Ml7YbY5pcWKrdIOgeIhmKGe{b4f0bC=> NXzYc4dpOjR7ME[xN|c>
Me007 NEO3WpZCeG:ydH;zbZMh[XO|YYm= MUL+NVAxKM7:TR?= MmjPSG1UVw>? M{ntOYlv\HWlZYOgZZBweHSxc3nz NVTaTWlOOjR7ME[xN|c>
SK-Mel-28 MnfQRZBweHSxc3nzJIF{e2G7 NUXGOohohjFyMDFOwG0> Ml\ZSG1UVw>? MYrpcoR2[2W|IHHwc5B1d3Orcx?= NGG2S2IzPDlyNkGzOy=>
Mel-RMU M4PCeWFxd3C2b4Ppd{Bie3OjeR?= NV\nRWplhjFyMDFOwG0> M1izTWROW09? MnH0bY5lfWOnczDhdI9xfG:|aYO= MlTXNlQ6ODZzM{e=
Mel-JD NIPYe3hCeG:ydH;zbZMh[XO|YYm= MoTrglExOCEQvF2= MXrEUXNQ NHjr[llqdmS3Y3XzJIFxd3C2b4Ppdy=> MVOyOFkxPjF|Nx?=
Mel-RM MnWxRZBweHSxc3nzJIF{e2G7 NW[5TmJYhjFyMDFOwG0> MmO1SG1UVw>? Mln3bY5lfWOnczDhdI9xfG:|aYO= NHmwO3czPDlyNkGzOy=>
Me007 M1rWdGZ2dmO2aX;uJIF{e2G7 Mmi4NVAh|ryP MmW0SG1UVw>? M1\udolv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgZpkhfXC{ZXf1cIF1cW:wIH;mJJAzOQ>? NEPBWFMzPDlyNkGzOy=>
SK-Mel-28 M1n2d2Z2dmO2aX;uJIF{e2G7 MnO5NVAh|ryP M3y0VGROW09? M2qyR4lv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgZpkhfXC{ZXf1cIF1cW:wIH;mJJAzOQ>? M{j4fVI1QTB4MUO3
Mel-RMU NXLGNolJTnWwY4Tpc44h[XO|YYm= MoPkNVAh|ryP MoDmSG1UVw>? MVHpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2IHL5JJVxemWpdXzheIlwdiCxZjDwNlE> MmfxNlQ6ODZzM{e=
Mel-JD NFTHZmNHfW6ldHnvckBie3OjeR?= NV;hW5BvOTBizszN MlTWSG1UVw>? MlTsbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dDDifUB2eHKnZ4XsZZRqd25ib3[gdFIy NUnC[nhOOjR7ME[xN|c>
Mel-RM NIPkR2FHfW6ldHnvckBie3OjeR?= NEPhd3AyOCEQvF2= MkDYSG1UVw>? M2T2[Ilv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgZpkhfXC{ZXf1cIF1cW:wIH;mJJAzOQ>? MkXPNlQ6ODZzM{e=
Me007 M1jRWmZ2dmO2aX;uJIF{e2G7 M3H4ZVExKM7:TR?= MoflSG1UVw>? NIKyWoV2eHKnZ4XsZZRmeyCycn;hdI9xfG:2aXOgZY5lKGOnbHygZ5lkdGViYYLy[ZN1KGenbnXz MWeyOFkxPjF|Nx?=
SK-Mel-28 Mn;RSpVv[3Srb36gZZN{[Xl? NYnLWFQ1OTBizszN M4nzUGROW09? M{fRVJVxemWpdXzheIV{KHC{b3Hwc5B1d3SrYzDhcoQh[2WubDDjfYNt\SCjcoLld5Qh\2WwZYO= NEnrWZAzPDlyNkGzOy=>
Mel-RMU MUnGeY5kfGmxbjDhd5NigQ>? MmjyNVAh|ryP M3PEPWROW09? MkjseZBz\We3bHH0[ZMheHKxYYDvdJRwfGmlIHHu[EBk\WyuIHP5Z4xmKGG{cnXzeEBo\W6ncx?= Mm\VNlQ6ODZzM{e=
Mel-JD MUPGeY5kfGmxbjDhd5NigQ>? Mk\kNVAh|ryP MYrEUXNQ M1zObZVxemWpdXzheIV{KHC{b3Hwc5B1d3SrYzDhcoQh[2WubDDjfYNt\SCjcoLld5Qh\2WwZYO= MnrXNlQ6ODZzM{e=
Mel-RM NFzKTZBHfW6ldHnvckBie3OjeR?= MUixNEDPxE1? MlvJSG1UVw>? MXv1dJJm\3WuYYTld{Bxem:jcH;weI91cWNiYX7kJINmdGxiY4njcIUh[XK{ZYP0JIdmdmW| Mn[yNlQ6ODZzM{e=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
α-SMA / Fibronectin / Collagen-1; 

PubMed: 27732564     


Normally cultured NRK-49F cells were treated with I-BET151 (0-5μM) for 36 h. Then, cell lysates were prepared and subjected to immunoblot analysis with antibodies against α-SMA, collagen-1, fibronectin, and GAPDH.

FoxM1 / AURKB / Survivin / cyclin B / PLK1; 

PubMed: 26877780     


OVTOKO and OVCA420 cells were treated with DMSO, JQ1 (1 μM) or I-BET151 (1 μM). Cell lysates were immunoblotted with indicated antibodies. 

HP1α / HP1β / HP1γ; 

PubMed: 30386240     


Protein expression levels of HP1α, β, and γ in U937, R-U937, HL-60, and R-HL-60 cells after incubation with I-BET151 at indicated dose for 48 h. Typical blots from a representative experiment are shown. The experiments were repeated three times.

27732564 26877780 30386240
体内研究 I-BET151每天按30 mg/kg剂量处理小鼠,显著抑制鼠类MLL-AF9和人类MLL-AF4白血病肿瘤生长,显著延长寿命。[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

- 合并

荧光各向异性(FP)的配体位移检测:

所有组分溶解在50 mM HEPES pH 7.4, 150 mM NaCl和 0.5 mM CHAPS组成的Buffer中,BRD 2/3/4终浓度为75 nM,荧光配体为5 nM。在Greiner 384孔黑色的低量微孔板中,使用Micro Multidrop 将10 μL反应混合物加入到含100 nL各种浓度I-BET151或DMSO空白对照(1%最终)的孔中,并在黑暗中室温下平衡60分钟。使用 Envision (lex=485 nm,lEM=530 nm;Dichroic=505 nM)读取荧光各向异性。
细胞实验:

[1]

- 合并
  • Cell lines: MV4;11, MOLM13, NOMO1, RS4;11, HEL, HL60 和 K562
  • Concentrations: 溶于DMSO, 终浓度为~100 μM
  • Incubation Time: 24,或72小时
  • Method:

    使用多种不同浓度I-BET151在384孔或96孔板中处理细胞24或72小时。细胞生长抑制实验中,实验板每孔中加入与细胞培养基同等体积的CellTiter-Glo试剂,震荡约2分钟,然后在Analyst GT 或EnVision酶标仪上读取化学发光信号。细胞增殖实验中,每孔加入CellTiter-Aqueous One,然后实验板在37°C下温育4小时。在SpectraMax Gemini酶标仪上490 nm处读取吸光度。


    (Only for Reference)
动物实验:

[1]

- 合并
  • Animal Models: 静脉注射MV4;11细胞的NOD-SCID小鼠,静脉注射MLL-AF9细胞的C57BL/6小鼠
  • Dosages: ~30 mg/kg/day
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 Ethanol 27 mg/mL (64.99 mM)
DMSO Insoluble
Water Insoluble

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 415.44
化学式

C23H21N5O3

CAS号 1300031-49-5
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

Epigenetic Reader Domain Signaling Pathway Map

Epigenetic Reader Domain Inhibitors with Unique Features

Tags: 购买I-BET151 (GSK1210151A) | I-BET151 (GSK1210151A)供应商 | 采购I-BET151 (GSK1210151A) | I-BET151 (GSK1210151A)价格 | I-BET151 (GSK1210151A)生产 | 订购I-BET151 (GSK1210151A) | I-BET151 (GSK1210151A)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID